T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

di Ladoire, S, Arnould, L, Mignot, G, Apetoh, L, Rébé, C, Martin, F, Fumoleau, P, Coudert, B, Ghiringhelli, F
Pubblicazione 2011

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

di Végran, F, Boidot, R, Coudert, B, Fumoleau, P, Arnould, L, Garnier, J, Causeret, S, Fraise, J, Dembélé, D, Lizard-Nacol, S
Pubblicazione 2009

Carcinomatous Meningitis from Unknown Primary Carcinoma

di Favier, L., Ladoire, L., Guiu, B., Arnould, L., Guiu, S., Boichot, C., Isambert, N., Besancenot, J.F., Muller, M., Ghiringhelli, F.
Pubblicazione 2009

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

di Guiu, S, Gauthier, M, Coudert, B, Bonnetain, F, Favier, L, Ladoire, S, Tixier, H, Guiu, B, Penault-Llorca, F, Ettore, F, Fumoleau, P, Arnould, L
Pubblicazione 2010

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer

di Arnould, L, Denoux, Y, MacGrogan, G, Penault-Llorca, F, Fiche, M, Treilleux, I, Mathieu, M C, Vincent-Salomon, A, Vilain, M O, Couturier, J
Pubblicazione 2003

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

di Arnould, L, Gelly, M, Penault-Llorca, F, Benoit, L, Bonnetain, F, Migeon, C, Cabaret, V, Fermeaux, V, Bertheau, P, Garnier, J, Jeannin, J-F, Coudert, B
Pubblicazione 2006

Increase of CD4(+)CD25(+) regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eli...

di Audia, S, Nicolas, A, Cathelin, D, Larmonier, N, Ferrand, C, Foucher, P, Fanton, A, Bergoin, E, Maynadie, M, Arnould, L, Bateman, A, Lorcerie, B, Solary, E, Chauffert, B, Bonnotte, B
Pubblicazione 2007